

Overview on Causes and Management of Neonatal Meningitis

Abstract:

Meningitis is more common in the neonatal period than at any extra time. The newborn is particularly liable to infection as the immature immune system is deficient in humoral and cellular immune answers in phagocytic and in complement functions. In developed countries, mortality has dropped from nearly 50% in the 1970s to <10% , but morbidity leftovers substantial, and 20–58% of survivors will have serious neurological sequelae, such as deafness. Diagnosis of meningitis jerks with a physical inspection and a review of the patient's health history for any of the signs mentioned above. Although patients with viral meningitis usually do not necessity to be hospitalized, treatment should be provided, such as antipyretics, antiemetics, and analgesics, which can be taken at home.

Keywords: Neonatal bacterial meningitis, Very low birth weight, Lumbar puncture, Cerebrospinal fluid, Antibiotics, Vaccine.

Introduction:

The major burden of neonatal sepsis and meningitis happens in the developing world, but most evidence derives from wealthy countries although the range of disease, aetiology and prognosis may differ. WHO estimates that here are approximately 5 million neonatal deaths a year. The overwhelming mainstream (98%) occur in developing countries [1-2-3]. Neonatal meningitis donates significantly to the burden of neonatal morbidity and death, and other causes include other infection, prematurity and birth asphyxia. The true occurrence of neonatal bacterial meningitis may be undervalued, particularly in resource-poor settings for multiple reasons. These include trouble in diagnosing neonatal meningitis, differences between hospital-based and public studies, regional differences and unregistered deaths in areas where admission to health care is poor

[4]. There is no consensus on the meaning of the neonatal or early infant period. Many studies define the neonatal period as up to 30 or 90 days of age, and WHO defines 'young infant', as ≤ 60 days. Within these boundaries, it is estimated there are 126 000 cases of neonatal meningitis yearly, and more than 50 000 deaths [1-3]. Mortality rates vary by area, e.g. 0.7–1.9/1000 live births in sub-Saharan Africa, 0.33–1.5 in the Middle East and North Africa and 0.4-2.8 in the Americas and Caribbean [1].

Meningitis is more common in the neonatal period than at any other time [5]. The newborn is particularly susceptible to infection as the undeveloped immune system is deficient in humoral and cellular immune responses in phagocytic and in complement functions [6]. In developed countries, mortality has dropped from nearly 50% in the 1970s to $<10\%$ [7-8-9], but morbidity remains substantial, and 20–58% of survivors will have serious neurological sequelae, such as deafness [7-6-10-9-11]. Death in the developing world remains unacceptably high, inconsistently reported as 40–58% [12-13]. Morbidity is under reported but supposed to be considerable.

Neonatal meningitis is a serious problem with a high death and frequent

neurological sequelae. The incidence of neonatal meningitis was investigated and the etiology, clinical and laboratory features, and the management of cases recorded prospectively over a 7 year 8 month period was predictable. It was further investigated whether secondary meningitis had arisen after lumbar puncture. The estimated occurrence of bacterial, viral, and fungal meningitis was 0.25, 0.11, and 0.02 per 1000 live births correspondingly [14].

In spite of the growth of the rapid diagnosis of pathogens and new antibiotics, neonatal meningitis (NM) contributes to neonatal death and morbidity worldwide. Neonatal meningitis is the inflammation of the meninges throughout the first 28 days of life [15]. According to the time of diagnosis, it is classified as early onset (EOM) or late onset meningitis (LOM). In EOM, clinical signs appear during the first weeks of life. LOM occurs between 8–28 postnatal times [16-17]. The incidence of neonatal bacterial meningitis varies from 0.25 to 1 per 1000 live birth

and occurs in 25% of neonates with bacteremia [18-19]. In established countries, group B streptococci (GBS) are the most common reasons of bacterial meningitis, accounting for 50% of all cases. Escherichia Coli (E. Coli) accounts for another 20%. Thus, identification and treatment of maternal genitourinary contagions is an important prevention strategy [20]. In emerging countries, gram-negative bacilli such as Klebsiella and E. Coli may be more common than GBS particularly in LOM [21-22]. In addition, other organisms that have been occupied as a cause of meningitis include Enterobacter spp., Citrobacter spp., and Serratia spp. Meningitis is repeatedly more severe with gram-negative bacteria and with a higher rate of mortality and morbidity [23]. Diagnosis of NM is founded on both clinical manifestations and cerebrospinal fluid (CSF) inspection. CSF culture is an excellent exam for demonstration of meningitis. Assessment of leukocyte count, glucose, and protein levels in the CSF may help in the diagnosis [24]. This schoolwork evaluates neonates who were acknowledged with meningitis from 2008 to 2012 in our tertiary center. We evaluated maternal and neonatal risk aspects, clinical manifestations, pathogens, and neurologic complications of neonatal meningitis suitcases.

Symptoms of meningitis in babies:

The symptoms of meningitis can come on very quickly. Your baby may be hard to comfort, especially when they're being held. Other symptoms in a baby may contain:

- developing a abrupt high fever
- not eating fine
- vomiting
- being less active or energetic than usual
- being very sleepy or hard to wake up
- being more irritable than usual
- bulging of the soft spot on their head (the fontanel)

Other symptoms may be hard to notice in a baby, such as:

- severe headache
- neck stiffness
- sensitivity to bright light

Irregularly, a baby may have a seizure. Many times this is due to the high fever and not the meningitis itself.

Causes of meningitis in babies:

Bacteria, viruses, or a fungus can cause meningitis in a baby. Viral meningitis has long been the most mutual cause of meningitis. Since the development of vaccines to prevent bacterial meningitis, this type of meningitis has developed increasingly uncommon. Fungal meningitis is occasional.

1-Viral meningitis:

Meningitis is an inflammation that affects the three defensive membrane layers that cover the brain and spinal cord, called the meninges [25]. The external layer of the meninges is called the dura mater, trailed by the arachnoid mater and the pia mater. The two inner layers (arachnoid and pia mater) are also termed the leptomeninges and are separated by the subarachnoid space, which holds cerebrospinal fluid (CSF) [26]. Aseptic meningitis, also known as slow viral disease, became an part of interest at the beginning of the 1950s, when it was considered a possible model for chronic nervous system diseases [27]. Bacteria are the most mutual causative agents of meningitis. However, viruses, fungi, and non-infectious mediators such as drugs can also induce meningitis [26]. Pathogens can scope the CSF through hematogenous spread by two main mechanisms: 1) by infecting immune cells, which in crack carry the pathogen to the nervous system, and 2) by trip blood capillaries and entering the CSF as free pathogens [28]. The term aseptic

meningitis is used to define meninges inflammation that is caused by pathogens additional than pus-producing bacteria [29]. Viral meningitis is the most common type of aseptic meningitis and typically affects young children [25]. Enteroviruses (EVs) are the greatest common causative agents of viral meningitis, with an estimated 75,000 new cases yearly in the United States [30]. Here, we provide an overview of viral meningitis and its greatest common causative agents and their pathogenesis. We also deliberate epidemiological aspects, diagnosis, and clinical displays of the disease.

Viral meningitis usually isn't as thoughtful as bacterial or fungal meningitis, but some viruses do cause a severe infection. Common viruses that typically cause mild disease include:

1-Non-polio enteroviruses. These viruses source most cases of viral meningitis in the United States. They cause many types of infections, including colds. A lot of people contract them, but very insufficient get meningitis. The viruses spread when your baby comes in contact with ill stool or oral secretions.

2-Influenza. This virus causes the flu. It's feast through contact with secretions from the lung or mouth of a person diseased with it.

3-Measles and mumps viruses. Meningitis is a rare difficulty of these very contagious viruses. They're easily spread finished contact with infected oozes from the lungs and mouth.

Viruses that can cause very severe meningitis contain:

1-Varicella. This virus causes chickenpox. It's easily blowout by contact with a person infected with it.

2-Herpes simplex virus. A baby usually gets it from their mother in the womb or during birth.

3-West Nile virus. This is conveyed by a mosquito bite.

Children under 5, including babies, have a higher risk of receiving viral meningitis. Babies between birth and 1 month of age are more likely to mature a severe viral infection.

2-Bacterial meningitis:

Bacterial meningitis is a devastating infection related with high mortality and morbidity in the neonatal population. Prompt diagnosis and conduct are essential to achieving good outcomes in affected infants. While overall occurrence and mortality have declined over the last several decades, morbidity related with neonatal meningitis remains nearly unchanged[31-32]. Neonatal bacterial meningitis is an uncommon. Although the incidence and mortality have deteriorated over the last several decades, morbidity among survivors remains high. The natures and distribution of causative pathogens are related to birth gestational oldness, postnatal age, and geographic region. Confirming the finding of meningitis can be difficult. Clinical signs are often subtle, and the lumbar puncture is habitually deferred in clinically unstable infants. When obtained, assenting testing with cerebrospinal fluid (CSF) culture is often cooperated by antepartum or postnatal antibiotic exposure. While blood cultures and CSF limits may be helpful in cases where the diagnosis is uncertain, bacterial meningitis occurs in newborns without bacteremia and with normal CSF limits. Newer tests such as the polymerase chain reaction are promising but require further study. Prompt action with appropriate antibiotics is essential to optimize outcomes. Successful efforts to stop meningitis in infants have included the use of intrapartum antibiotic prophylaxis in contradiction of Group B *Streptococcus* (GBS)[33].

During the first 28 days of life, bacterial meningitis is most often produced by bacteria called:

1-Group B *Streptococcus*. This usually binges from a mother to her baby at birth.

2-Gram-negative bacilli, such as *Escherichia coli* (*E. coli*) and *Klebsiella pneumoniae*. *E. coli* can spread via unclean food, food prepared by someone who used the bathroom without washing their hands then, or from mother to baby during birth.

3-*Listeria monocytogenes*. Neonates usually get this from their mom in the womb. Infrequently a baby may get it during delivery. The mother gets it by eating contaminated nutrition.

In children under 5 years, including babies over 1 month old, the most mutual bacteria that cause meningitis are:

1-*Streptococcus pneumoniae*. This bacterium is found in the sinuses, nose, and lungs. It spreads through breathing in air that a person diseased with it sneezed or coughed into. It's the most common origin of bacterial meningitis in babies younger than 2 years.

2-*Neisseria meningitidis*. This is the second most mutual cause of bacterial meningitis. It spreads through contact with oozes from the lungs or mouth of a person infected with it. Babies less than 1 year old are at uppermost risk of getting this.

3-*Haemophilus influenzae* type b (Hib). This is spread by interaction with secretions from the mouth of a person who's a hauler. Carriers of the bacteria usually aren't sick themselves but can make you tasteless. A baby must be in close contact with a carrier for a couple days to grow it. Even then, most babies will only become carriers and not become meningitis.

3-Fungal meningitis:

Fungal meningitis is very rare because it usually only moves people with a weak immune system. Several types of fungi can cause meningitis. Three sorts of fungus live in the soil, and one type lives around bat and bird excreta. The fungus enters the body by being breathed in. Babies born prematurely who don't balance

very much have a higher risk of getting a blood impurity from a fungus called *Candida*. A baby usually contracts this fungus in the hospital after birth. It can then portable to the brain, causing meningitis.

Although overall survival rates among very low birth heaviness (VLBW) premature infants have improved during the past period, nosocomial infections continue to have an adverse effect on the consequence for these developmentally immuno compromised hosts [34]. Of these infections, disseminated or universal candidiasis is a major cause of morbidity and mortality. A shift in the pathogenic classes of *Candida* causing systemic neonatal disease recently has been reported, with more contagions caused by non-*albicans* species [35-36]. CNS involvement is a complication of dispersed candidiasis that may be associated with enhanced morbidity, and the amount of cases of candidal meningitis in VLBW infants appears to be snowballing [36-37]. However, little is known about risk factors, clinical features, laboratory findings, management, and outcome of candidal meningitis in these newborns.

4-Aseptic meningitis:

When a toxic newborn or young infant offerings with fever and lethargy or irritability, it is important to consider the diagnosis of meningitis level if the classic localizing signs and symptoms are absent. Cerebrospinal fluid would be obtained (unless lumbar puncture is clinically contraindicated) to enable first therapy to be planned. Initial results of cerebrospinal fluid testing may not decisively differentiate between aseptic and bacterial meningitis, and antimicrobial rehabilitation for all likely organisms should be instituted until definitive culture fallouts are available. Comprehensive therapy, including antiseptic and antiviral agents, should continue until a cause is identified and more specific therapy is began, an etiology is excluded or the patient improves considerably and the passage of antimicrobial therapy is completed. Group B streptococcus is the most mutual bacterial etiologic agent in cases of meningitis that occur throughout the first month after birth. Etiologies of aseptic meningitis include viral infection, partially preserved bacterial meningitis, congenital infections, drug responses, postvaccination complications, systemic

illnesses and malignancy. Long-term sequelae of meningitis include neuromuscular impairments, learning disabilities and hearing loss. Quick diagnosis and treatment are essential to improved consequence [38].

Diagnosis:

1-Diagnosis of viral meningitis:

Diagnosis of meningitis starts with a bodily examination and a review of the patient's health antiquity for any of the signs mentioned above. A recent and less recognized physical scrutiny technique that has been developed to assess meningeal irritation is known as jolt prominence of annoyance. A systematic review done by Iguchi and colleagues showed that jolt accentuation can be used in emergency settings to exclude meningitis. But, the pooled sensitivity and specificity of this exam (65.3%, 70.4% respectively) are considered low, and more research is needed to assess its expediency [39]. To test for etiological agents, a lumbar puncture and collection of CSF is wanted. The procedure is performed while the patient is in a lying or sitting location, and a hollow needle is injected into the subarachnoid space between spines L3, L4 or L5, where the CSF is aspirated [40]. The CSF is then tested to regulate red blood cell and leukocyte count as well as the glucose and protein points. The cell counts typically help in differentiating the different types of meningitis. For illustration, a high WBC count (≥ 500 cells/ μ l) with a large amount of neutrophils ($>80\%$) is usually observed in bacterial meningitis.

2-Diagnosis of bacterial meningitis:

To confirm the diagnosis of neonatal meningitis, an LP is wanted to collect CSF. Positive growth on the CSF culture provides identification of the offending creature and enables refinement of therapy[41-42].The LP is frequently deferred during the septic diagnosis due to concerns of exacerbating clinical worsening in the sick infant [42-43].

Performing or Deferring the LP:

Because the LP is an invasive technique with dangers, it is difficult to determine which infant should receive one as part of the septic workup[44-45]. Amid infants with positive blood cultures, up to 30% will have a simultaneous positive CSF culture[46]. However, in infants with established meningitis, 15–38% will have a negative blood culture[47-48-49]

Interpreting CSF Parameters:

Infants are often exposed to intrapartum or empiric antibiotics prior to receiving an LP, which can result in falsely negative CSF findings in those with meningitis[50]. In these cases, CSF restrictions are used to help determine the likelihood of meningitis.

Ancillary Tests:

The polymerase chain reaction (PCR) has been utilised as a diagnostic tool for meningitis. In addition to better sensitivity and specificity, PCR also allows quicker detection of pathogens compared with old-style cultures[51].

Management of meningitis:

1-Treatment of the viral meningitis:

Although patients with viral meningitis usually do not need to be hospitalized, treatment should be provided, such as antipyretics, antiemetics, and analgesics, which can be taken at home. However, some patients, such as those who suffer from seizures, need to be under medical management [52]. Although corticosteroids are commonly given in cases of suspected bacterial meningitis to decrease the inflammatory effect that accompanies the disease, there is a want of evidence of their efficacy against viral meningitis, and more trainings are still needed [53]. Pleconaril is an antiviral drug that acts as an inhibitor of enterovirus duplication by targeting the viral capsid structure [54]. It is accepted as intranasal therapy for the common cold, but it attains several-fold higher concentrations in the CNS, making it a potential treatment for brain-related illnesses such as meningitis [55]]. Several studies have shown that pleconaril plays a significant role in shortening the course

of symptoms, especially headache [56-55]. However, additional studies have shown that there was no significant difference between management and placebo groups[57]. The FDA did not approve the oral custom of the drug because it induces CYP3A enzyme activity, resulting in a drug communication, especially with oral contraceptives [58].

In a study done in the UK, students found that the median distance of hospital stay was 4 days for patients with viral meningitis and nine days for those under antiviral therapy. They also decided that delays in performing lumbar puncture and unnecessary managements were associated with prolonged hospital stays and long-term morbidity [59]. No precise treatment is prescribed for aseptic meningitis cases, and supportive medications are usually given to minimalize disease complications such as fever and headache, and full recovery receipts from 5 to 14 days in the majority of cases [60]. Regarding to HSV management, one study showed that antiviral rehabilitation in immunocompromised patients with HSV-induced meningitis should be started nearly and that any delay in the administration of treatment can result in the development of contrary complications [61]. The use of acyclovir against HSV-2-induced meningitis was also estimated, with better outcomes observed in treated patients. However, one tolerant developed concentration problems as a meningitis symptom that lasted for approximately three months [62]. Recently, a promising drug named psoromic acid (a bioactive lichen-derived compound) has been found to inhibit the duplication of both HSV-1 and HSV-2 by inhibiting proteases and DNA polymerases, which brands it a possible drug for treating meningitis produced by HSV [63]. Valacyclovir was also tested in clinical trials for its antiviral suppression ability on reappearance of meningitis. However, treatment with valacyclovir (twice daily) did not prevent recurring meningitis and was not recommended for this determination [64, 65]. Some vaccines have been developed for some germs such as EV-71 [66].

2-Treatment of the bacterial meningitis:

Antimicrobial Therapy:

Prompt initiation of antibiotics is critical. Interruptions in treatment are associated with increased mortality and morbidity[67]. Empiric antimicrobials used in assumed meningitis require adequate CSF penetration and sensitivity alongside the most probable pathogens[68]. Upon documentation of the pathogen and its susceptibilities, antimicrobial reporting should be adjusted accordingly.

Duration of Antimicrobial Therapy:

For uncomplicated meningitis, the minimum optional treatment durations are the following[69-70-71].

- 14 days for GBS, *L. monocytogenes*, and *S. pneumonia*
- 21 days for *Pseudomonas* and gram-negative enteric bacteria such as *E. coli*

Longer treatment courses are optional for infants with meningitis with delayed clinical improvement after beginning healing or with complications such as brain abscesses, ventriculitis, or brain infarction[72].

Adjunctive Therapy:

In an effort to improve penalties in infants with meningitis, several adjunctive therapies have been explored, with the use of intraventricular antibiotics, dexamethasone, intravenous immunoglobulins, granulocyte or granulocyte macrophage colony stimulating factor, and oral glycerol[73]. At current, none of the proposed adjunctive therapies are rummage-sale in routine practice.

Conclusion:

Meningitis is more common in the neonatal period than at any extra time. In developed countries, mortality has dropped, but morbidity leftovers substantial, with serious neurological sequelae. Although patients with viral meningitis usually do not necessity to be hospitalized, treatment should be provided, such as antibiotics, antipyretics, antiemetics, and analgesics, which can be taken at home.

References:

- 1-Stoll B (1997) The global impact of neonatal infection. *Clinics in Perinatology* **24**, 1– 21.
- 2-WHO (1999a) World Health Organization Young Infants Study Group. Clinical prediction of serious bacterial infections in young infants in developing countries. *Pediatric Infectious Disease Journal* **18**(Suppl. 10), S23– S31.
- 3-Weber MW, Carlin JB, Gatchalian S *et al.* (2003) Predictors of neonatal sepsis in developing countries. *Pediatric Infectious Disease Journal* **22**, 711– 716.
- 4-Osrin D, Vergnano S & Costello A (2004) Serious bacterial infections in newborn infants in developing countries. *Current Opinion Infectious Diseases* **17**, 217– 224.
- 5-Delouvois J, Blackbourn J, Hurley R *et al.* (1991) Infantile meningitis in England and Wales: a two year study. *Archives of Disease in Childhood* **66**, 603– 607.
- 6-Pong A & Bradley JS (1999) Bacterial meningitis and the newborn infant. *Infectious Disease Clinics of North America*. **13**, 712– 733.
- 7-Harvey D, Holt D & Bedford H (1999) Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. *Seminars in Perinatology* **23**, 218– 225.
- 8-Holt D, Haket S, Louvouis JD *et al.* (2001) Neonatal meningitis in England and wales: ten years on. *Archives of Disease in Childhood. Fetal and Neonatal Edition* **84**, F85– F89.
- 9-Polin R & Harris M (2001) Neonatal bacterial meningitis. *Seminars in Neonatology* **6**, 157– 172.
- 10-Bedford H, Louvois Jd, Halket S *et al.* (2001) Meningitis in infancy in England and Wales: follow up at age 5 years. *BMJ* **323**, 533– 536.
- 11-Heath P, Yusoff NN & Baker C (2003) Neonatal meningitis. *Archives of Disease in Childhood. Fetal and Neonatal Edition* **88**, F173– F178.
- 12-Campagne G (1999) Epidemiology of bacterial meningitis in niamey, Niger 1981–96. *WHO - Bulletin of WHO* **77**, 499– 508.
- 13-Milledge J, Calis JCJ, Graham S *et al.* (2005) Aetiology of neonatal sepsis in Blantyre, Malawi: 1996–2001. *Annals of Tropical Paediatrics* **25**, 101– 110.

- 14-Hristeva, L., Booy, R., Bowler, I., Wilkinson, A.R.(1993): Prospective surveillance of neonatal meningitis Archives of Disease in Childhood 1993; 69: 14-18
- 15- Volpe JJ. *Neurology of the Newborn*. 5th Edition. Philadelphia, Pa: Saunders Elsevier; 2008. Bacterial and fungal intracranial infections; pp. 916–56. [[Google Scholar](#)]
- 16- Aletayeb M, Farajzadeh S, Dehdashtian M. Eleven-year study of causes of neonatal bacterial meningitis in Ahvaz, Iran. *Pediatrics International*. 2010;52:463–466. [[PubMed](#)] [[Google Scholar](#)]
- 17-Edwards MS, Baker CJ. Sepsis in the newborn. In: Gershon A, Hotez PJ, Katz SL, editors. *Krugman's Infectious Diseases of Children*. 11th edition. Philadelphia: Mosby; 2004. pp. 545–561. [[Google Scholar](#)]
- 18- Hristeva L, Booy R, Bowler I, Wilkinson AR. Prospective surveillance of neonatal meningitis. *Arch Dis Child*. 1993;69:14–8. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- 19- Klein JO. Bacterial meningitis and sepsis. In: Remington JS, Klein JO, editors. *Infectious Diseases of the Fetus and Newborn Infant*. 4th edition . Philadelphia, PA. WB Saunders; 2006. pp. 943–98. [[Google Scholar](#)]
- 20- Klinger G, Chin CN, Beyene J, et al. Predicting the outcome of neonatal bacterial meningitis. *Pediatrics*. 2000 Sep;106(3):477–82. [[PubMed](#)] [[Google Scholar](#)]
- 21- Tiskumara R, Fakharee SH, Liu C-Q, Nuntnarumit P, Lui K-M, Hammoud M, et al. Neonatal infections in Asia. *Arch Dis Child Fetal Neonatal Ed*. 2009 Mar;94:144–8. [[PubMed](#)] [[Google Scholar](#)]
- 22-Zaidi AK, Thaver D, Ali SA, Khan TA. Pathogens associated with sepsis in newborns and young infants in developing countries. *Pediatr Infect Dis J*. 2009 Jan;28(1Suppl):S10–8. [[PubMed](#)] [[Google Scholar](#)]
- 23- Muhe L, Tilahun M, Lulseged S, et al. Etiology of pneumonia, sepsis, and meningitis in infants younger than three months of age in Ethiopia. *Pediatric Infect Dis J*. 1999;18(Suppl. 1):56–61. [[PubMed](#)] [[Google Scholar](#)]
- 24-Garges HP, Moody MA, Cotten CM, et al. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? *Pediatrics*. 2006 Apr;117(4):1094–100. [[PubMed](#)] [[Google Scholar](#)]

- 25-Logan SA, MacMahon E (2008a) Viral meningitis. *BMJ* 336(7634):36–40
- 26-Hoffman O, Weber JR (2009) Pathophysiology and treatment of bacterial meningitis. *Ther Adv Neurol Disord* 2(6):401–412
- 27-Booss J, Tselis AC (2014) Chapter 1—a history of viral infections of the central nervous system: foundations, milestones, and patterns. In: Tselis AC, Booss J (eds) *Handbook of clinical neurology*, vol 123. Elsevier, pp 3–44. <https://doi.org/10.1016/B978-0-444-53488-0.00001-8>
- 28-Hersi K, Gonzalez FJ, Kondamudi NP. Meningitis. [Updated 2020 Nov 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459360>
- 29-Kumar R (2005) Aseptic meningitis: diagnosis and management. *Indian J Pediatr* 72(1):57–63
- 30-Desmond R et al (2006) Enteroviral meningitis: natural history and outcome of pleconaril therapy. *Antimicrob Agents Chemother* 50(7):2409–2414
- 31- Polin RA, Harris MC. Neonatal bacterial meningitis. *Semin Neonatol*. 2001;6:157–172. [PubMed] [Google Scholar]
- 32-Heath PT, Okike IO, Oeser C. Neonatal meningitis: can we do better? *Adv Exp Med Biol*. 2011;719:11–24. [PubMed] [Google Scholar]
- 33-Ku, L. C., Boggess, K.A., and Cohen-Wolkowicz, M., (2016):** Bacterial Meningitis in the Infant *Clin Perinatol*. 2015 Mar; 42(1): 29–45.
- 34-Stoll BJ, Gordon T, Korones SB, et al. Late onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network, *J Pediatr*, 1996, vol. 129 (pg. 63-71)
- 35-Rangel-Fausto MS, Wiblin T, Blumberg HM, et al. National Epidemiology of Mycosis Survey (NEMIS): variations in rates of bloodstream infections due to *Candida* species in 7 surgical intensive care units and 6 neonatal intensive care units, *Clin Infect Dis*, 1999, vol. 29 (pg. 253-8)
- 36-Kossoff EH, Buescher ES, Karlowicz G. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases, *Pediatr Infect Dis J*, 1998, vol. 17 (pg. 504-8)

37- Buchs S. Candida meningitis: a growing threat to premature and full term infants, *Pediatr Infect Dis J*, 1985, vol. 4 (pg. 122-3(

38- DANIS, P.G., GARDNER, T. D., (1999): Aseptic Meningitis in the Newborn and Young Infant *Am Fam Physician*. 1999 May 15;59(10):2761-2770

39- Iguchi M et al (2020) Diagnostic test accuracy of jolt accentuation for headache in acute meningitis in the emergency setting. *Cochrane Database Syst Rev*. <https://doi.org/10.1002/14651858.CD012824>

40- Walker HK, Hall WD, Hurst JW (eds) (1990) Clinical methods: the history, physical, and laboratory examinations. 3rd edn. Butterworths, Boston. PMID: 21250045

41-Heath PT, Okike IO, Oeser C. Neonatal meningitis: can we do better? *Adv Exp Med Biol*. 2011;719:11–24. [PubMed] [Google Scholar]

42-Stoll BJ, Hansen N, Fanaroff AA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. *Pediatrics*. 2004;113:1181–1186. [PubMed] [Google Scholar]

43-Weisman LE, Merenstein GB, Steenbarger JR. The effect of lumbar puncture position in sick neonates. *Am J Dis Child*. 1983;137:1077–1079. [PubMed] [Google Scholar]

44- Speidel BD. Adverse effects of routine procedures on preterm infants. *Lancet*. 1978;1:864–866. [PubMed] [Google Scholar]

45- Weisman LE, Merenstein GB, Steenbarger JR. The effect of lumbar puncture position in sick neonates. *Am J Dis Child*. 1983;137:1077–1079. [PubMed] [Google Scholar]

46- Visser VE, Hall RT. Lumbar puncture in the evaluation of suspected neonatal sepsis. *J Pediatr*. 1980;96:1063–1067. [PubMed] [Google Scholar]

47- Ansong AK, Smith PB, Benjamin DK, et al. Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis. *Early Hum Dev*. 2009;85:S5–S7. [PMC free article] [PubMed] [Google Scholar]

48-Newborn, et al. Committee on Infectious D, Committee on F. Policy statement- Recommendations for the prevention of perinatal group B streptococcal (GBS) disease. *Pediatrics*. 2011;128:611–616. [PubMed] [Google Scholar]

49- Smith PB, Garges HP, Cotton CM, et al. Meningitis in preterm neonates: importance of cerebrospinal fluid parameters. *Am J Perinatol*. 2008;25:421–426. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

50-Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. *Pediatrics*. 2001;108:1169–1174. [[PubMed](#)] [[Google Scholar](#)]

51-Backman A, Lantz P, Radstrom P, et al. Evaluation of an extended diagnostic PCR assay for detection and verification of the common causes of bacterial meningitis in CSF and other biological samples. *Mol Cell Probes*. 1999;13:49–60. [[PubMed](#)] [[Google Scholar](#)]

52- Kumar R (2005) Aseptic meningitis: diagnosis and management. *Indian J Pediatr* 72(1):57–63

53- Bookstaver PB et al (2017) Management of viral central nervous system infections: a primer for clinicians. *J Cent Nerv Syst Dis* 9:1179573517703342–1179573517703342

54- Pevear DC et al (1999) Activity of pleconaril against enteroviruses. *Antimicrob Agents Chemother* 43(9):2109

55-Romero JR (2001) Pleconaril: a novel antipicornaviral drug. *Expert Opin Investig Drugs* 10(2):369–379

56-Desmond R et al (2006) Enteroviral meningitis: natural history and outcome of pleconaril therapy. *Antimicrob Agents Chemother* 50(7):2409–2414

57-Abzug MJ et al (2003) Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. *Pediatr Infect Dis J* 22(4):335–341

58-Paintsil E, Cheng Y-C (2009) Antiviral agents. In: Schaechter M (ed) *Encyclopedia of microbiology* (Third Edition). Academic Press, Oxford, pp 223–257

59-McGill F et al (2018) Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study. *Lancet Infect Dis* 18(9):992–1003

60-Kumar R (2005) Aseptic meningitis: diagnosis and management. *Indian J Pediatr* 72(1):57–63

61-Momméja-Marin H et al (2003) Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults. *Clin Infect Dis* 37(11):1527–1533

62-Bergström T, Alestig K (1990) Treatment of primary and recurrent herpes simplex virus type 2 induced meningitis with acyclovir. *Scand J Infect Dis* 22(2):239–240

63-Hassan STS et al (2019) Psoromic acid, a lichen-derived molecule, inhibits the replication of HSV-1 and HSV-2, and inactivates HSV-1 DNA polymerase: shedding light on antiherpetic properties. *Molecules (Basel, Switzerland)* 24(16):2912

64-Aurelius E et al (2012) Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. *Clin Infect Dis* 54(9):1304–1313

65-Kato K et al (2015) Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: case report. *J Infect Chemother* 21(12):879–881

66-Yi E-J et al (2017) Enterovirus 71 infection and vaccines. *Clin Exp Vaccine Res* 6(1):4–14

67- Weisfelt M, de Gans J, van de Beek D. Bacterial meningitis: a review of effective pharmacotherapy. *Expert Opin Pharmacother*. 2007;8:1493–1504. [[PubMed](#)] [[Google Scholar](#)]

68-Heath PT, Okike IO. Neonatal bacterial meningitis: an update. *Paediatrics and Child Health*. 2010;20:526–530. [[Google Scholar](#)]

69- Heath PT, Okike IO. Neonatal bacterial meningitis: an update. *Paediatrics and Child Health*. 2010;20:526–530. [[Google Scholar](#)]

70- Pickering L, editor. Group B Streptococcal Infections. *Red Book: 2012 Report of the Committee on Infectious Disease*. 29th edition. Elk Grove: American Academy of Pediatrics; 2012. pp. 680–685. [[Google Scholar](#)]

71-Pickering L, editor. Escherichia coli and Other Gram-Negative Bacilli. *Red Book: 2012 Report of the Committee on Infectious Disease*. 29th edition. Elk Grove: American Academy of Pediatrics; 2012. pp. 321–324. [[Google Scholar](#)]

72- Stockmann C, Spigarelli MG, Campbell SC, et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. *Paediatr Drugs*. 2014;16:67–81. [[PubMed](#)] [[Google Scholar](#)]

73-Heath PT, Okike IO, Oeser C. Neonatal meningitis: can we do better? *Adv Exp Med Biol*. 2011;719:11–24. [[PubMed](#)] [[Google Scholar](#)]

UNDER PEER REVIEW